Diabetes groups have joined forces against moves to allow pharmacists to substitute biosimilar insulins, saying it has the potential to seriously disrupt diabetes management. The joint statement from the Australian Diabetes Education Association, the Australian Diabetes Society and Diabetes Australia is in response to a PBAC recommendation to list the biosimilar insulin glargine product Basaglar on ...
Type 1 diabetes
Diabetes groups opposed to pharmacist substitution of insulin
28 Oct 2015